Semaglutide studies: 1,194 papers with results
Page 22 of 24
- Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024.
Alibilli AS · JMIR infodemiology · 2025
Not a test of Semaglutide alone · 15 results
- Systemic Pharmacokinetic Principles of Therapeutic Peptides.
Nordell P · Clinical pharmacokinetics · 2026
Not a test of Semaglutide alone · 22 results
- Computational modelling the impact of GLP-1 receptor agonists on botulinum toxin A: Evidence for reduced treatment durability across neurologic and aesthetic indications.
Rahman E · Toxicon : official journal of the International Society on Toxinology · 2026
Not a test of Semaglutide alone · 20 results
- The Effect of GLP-1 Receptor Agonists on Alanine Aminotransferase and Other Metabolic Parameters in Youths with Obesity: A Systematic Review and Meta-Analysis.
Hertzer LA · Childhood obesity (Print) · 2026
Not a test of Semaglutide alone · 10 results
- Emulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population.
Schrage B · Journal of the American College of Cardiology · 2026
Not a test of Semaglutide alone · 5 results
- Exploring Dietary Intake in Adults with Type 2 Diabetes Using GLP-1 Receptor Agonists: A Cross-Sectional Analysis.
Ponzo V · Nutrients · 2025
Not a test of Semaglutide alone · 10 results
- Cost-effectiveness analysis of oral semaglutide versus subcutaneous dulaglutide in patients with type 2 diabetes mellitus: A Markov model study.
Hsu HY · Diabetes research and clinical practice · 2026
Not a test of Semaglutide alone · 9 results
- CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.
Gadelmawla AF · The American journal of cardiology · 2026
Not a test of Semaglutide alone · 10 results
- Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes.
Gulisano W · Journal of diabetes science and technology · 2026
Not a test of Semaglutide alone · 12 results
- Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study.
Bach P · The lancet. Psychiatry · 2026
Not a test of Semaglutide alone · 5 results
- Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.
Yovera-Aldana M · JCEM case reports · 2026
Not a test of Semaglutide alone · 16 results
- Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance.
Yang W · Medicine · 2024
Not a test of Semaglutide alone · 5 results
- Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.
Jensen AB · Obesity surgery · 2023
Not a test of Semaglutide alone · 8 results
- Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Zhou J · BMC medicine · 2024
Not a test of Semaglutide alone · 12 results
- Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.
Nreu B · Nutrition, metabolism, and cardiovascular diseases : NMCD · 2020
Not a test of Semaglutide alone · 8 results
- Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss.
Haseeb M · JAMA network open · 2024
Not a test of Semaglutide alone · 4 results
- Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).
Matza LS · Diabetes, obesity & metabolism · 2020
Not a test of Semaglutide alone · 4 results
- Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.
Guo H · Obesity pillars · 2025
Not a test of Semaglutide alone · 18 results
- Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Hansen BB · Journal of medical economics · 2020
Not a test of Semaglutide alone · 8 results
- Areas of Interest and Attitudes Toward Antiobesity Drugs: Thematic and Quantitative Analysis Using Twitter.
Alvarez-Mon MA · Journal of medical Internet research · 2021
Not a test of Semaglutide alone · 7 results
- Newer glucose-lowering drugs reduce the risk of late-onset seizure and epilepsy: A meta-analysis.
Sindhu U · Epilepsia open · 2024
Not a test of Semaglutide alone · 4 results
- Factors Associated With Semaglutide Initiation Among Adults With Obesity.
Podolsky MI · JAMA network open · 2025
Not a test of Semaglutide alone · 4 results
- The effects of weight-lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta-analysis of randomized controlled trials.
Jobanputra R · Obesity reviews : an official journal of the International Association for the Study of Obesity · 2023
Not a test of Semaglutide alone · 8 results
- Allocation of Semaglutide According to Coronary Artery Calcium and BMI: Applying the SELECT Trial to MESA.
Razavi AC · JACC. Cardiovascular imaging · 2025
Not a test of Semaglutide alone · 4 results
- Impact of glucagon-like peptide-1 receptor agonists on axonal function in diabetic peripheral neuropathy.
Dhanapalaratnam R · Journal of neurophysiology · 2025
Not a test of Semaglutide alone · 8 results
- Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants.
Almeida OP · Diabetes, obesity & metabolism · 2024
Not a test of Semaglutide alone · 8 results
- A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide.
Tham LS · Diabetes, obesity & metabolism · 2022
Not a test of Semaglutide alone · 9 results
- The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
Malkin SJP · Advances in therapy · 2019
Not a test of Semaglutide alone · 10 results
- Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis.
Gonzales-Uribe A · Clinical research in cardiology : official journal of the German Cardiac Society · 2026
Not a test of Semaglutide alone · 8 results
- Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes.
Wong G · JCEM case reports · 2023
Not a test of Semaglutide alone · 10 results
- Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors Improve Renal Resistive Index in Patients With Type 2 Diabetes: A 26-Week Prospective Observational Real-Life Study.
Vozza A · Journal of diabetes research · 2025
Not a test of Semaglutide alone · 4 results
- Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.
Arrowaili A · Obesity surgery · 2025
Not a test of Semaglutide alone · 11 results
- Newer Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Improved Glycemic Control in US Adults With Type 2 Diabetes: A Population-Level Time Series Analysis.
Lv L · Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2025
Not a test of Semaglutide alone · 12 results
- New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov.
Alshehri FS · Medicine · 2025
Not a test of Semaglutide alone · 8 results
- A Descriptive Analysis from VigiAccess on Drug-related Problems Associated with the Glucagon-like Peptide-1 Receptor Agonists.
Amirthalingam P · Current drug safety · 2026
Not a test of Semaglutide alone · 18 results
- Neuropathy of diabetes following initiation of a low-carbohydrate diet: Case report.
Sahyouni MJ · Obesity pillars · 2024
Not a test of Semaglutide alone · 4 results
- Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Obesity Without Diabetes.
Ali Akbar U · The American journal of cardiology · 2026
Not a test of Semaglutide alone · 12 results
- Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial.
Ji L · The lancet. Diabetes & endocrinology · 2026
Not a test of Semaglutide alone · 4 results
- Use of obesity medications in a young pediatric patient with optic nerve hypoplasia and severe early-onset obesity: A case report.
Simonian A · Obesity pillars · 2025
Not a test of Semaglutide alone · 4 results
- Long-Term Effects of Incretin-Based Drugs on Glycemic Control in Permanent Neonatal Diabetes.
Oshiro A · JCEM case reports · 2024
Not a test of Semaglutide alone · 4 results
- Glucagon-like peptide-1 receptor agonists in individuals with severe mental illness: A systematic review and meta-analysis of randomized controlled trials.
Srisurapanont M · International journal of psychiatry in medicine · 2026
Not a test of Semaglutide alone · 8 results
- Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.
Xu Y · Circulation · 2026
Not a test of Semaglutide alone · 8 results
- BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.
AlTaweel M · Current medical research and opinion · 2026
Not a test of Semaglutide alone · 4 results
- Clinical Outcomes Associated with GLP-1 Receptor Agonist Exposure in Non-Diabetic Patients with Chronic Pancreatitis: A Retrospective Cohort Study.
Dhali A · Journal of personalized medicine · 2026
Not a test of Semaglutide alone · 12 results
- Tirzepatide non-response with subsequent semaglutide response in class 2 obesity.
La Vignera S · JCEM case reports · 2026
Not a test of Semaglutide alone · 5 results
- Cardiometabolic risk effects of weight-loss medications: An updated network meta-analysis.
Wang J · Diabetes, obesity & metabolism · 2025
Not a test of Semaglutide alone · 9 results
- Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
Monami M · Diabetes, obesity & metabolism · 2017
Not a test of Semaglutide alone · 6 results
- Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
Xie Z · Metabolism: clinical and experimental · 2024
Not a test of Semaglutide alone · 32 results
- Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting.
Hu Y · Annals of translational medicine · 2022
Not a test of Semaglutide alone · 5 results
- Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
Qin J · BMC endocrine disorders · 2022
Not a test of Semaglutide alone · 6 results